Pfizer (PFE) Common Equity (2009 - 2026)

Pfizer has disclosed Common Equity across 18 years of filings, most recently posting $90.4 billion for Q1 2026.

• In Q1 2026, Common Equity changed 0.26% year-over-year to $90.4 billion; the TTM figure through Mar 2026 stood at $90.4 billion (changed 0.26% YoY), while the FY2025 annual figure was $86.8 billion, down 1.95% from the prior year.
• Common Equity grew to $90.4 billion in Q1 2026, from $86.8 billion in the prior quarter.
• Over the last five years, Common Equity for PFE reached as high as $101.2 billion in Q2 2023 and fell as low as $82.7 billion in Q2 2022.
• The 5-year median for Common Equity is $90.6 billion (2025), against an average of $91.6 billion.
• Annual changes were most pronounced in 2022 — Common Equity soared 160.16% — and 2024, when it declined 11.4%.
• A 5-year view of Common Equity shows it stood at $95.9 billion in 2022, then slipped by 6.91% to $89.3 billion in 2023, then declined by 0.89% to $88.5 billion in 2024, then slipped by 1.95% to $86.8 billion in 2025, then climbed by 4.18% to $90.4 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $90.4 billion, $86.8 billion, and $93.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.